0.75Open0.75Pre Close0 Volume112 Open Interest10.00Strike Price0.00Turnover113.19%IV14.85%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type0.4587Delta0.1586Gamma12.48Leverage Ratio-0.0251Theta0.0020Rho5.72Eff Leverage0.0088Vega
Foghorn Therapeutics Stock Discussion
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet